Table 1.
Baseline Characteristics of HIV-Infected Individuals Initiating ART
| All N = 533 | Not drinker N = 328 (61.5%) | Moderate N = 154 (28.9%) | Hazardous N = 51 (9.6%) | p Value* | |
|---|---|---|---|---|---|
| Median follow-up—years [IQR] | 1.65 [1.30–1.80] | 1.65 [1.26–1.80] | 1.65 [1.31–1.80] | 1.72 [1.43–1.85] | 0.405 |
| Median visits [IQR] | 10 [7–18] | 10 [7–18] | 9 [6–13] | 12 [8–30] | 0.049 |
| Mean age at HAART initiation (SD) | 42.80(10.21) | 44.11(9.86) | 40.37(10.93) | 41.68(8.84) | <0.001 |
| Men, % | 58.9 | 54.6 | 70.8 | 51 | 0.001 |
| Race, % | |||||
| African American | 84.2 | 85.1 | 82.5 | 84.3 | 0.487 |
| Other | 15.8 | 14.9 | 17.5 | 15.7 | |
| BMI, mean (SD) | 25.80(7.48) | 25.81(7.23) | 26.15(8.46) | 24.75(6.38) | 0.616 |
| BMI WHO categories, % | |||||
| <18.5 | 10.4 | 9.8 | 9.8 | 15.8 | 0.879 |
| 18.5–24.9 | 42.4 | 42.5 | 45.1 | 34.2 | |
| 25–29.9 | 26.6 | 27.2 | 25.5 | 26.3 | |
| >30 | 20.6 | 20.5 | 19.6 | 23.7 | |
| CD4 nadir cells/mm3 Median [IQR] | 181 [57–303] | 196 [56–302] | 163 [48–310] | 173 [70–290] | 0.594 |
| CD4 nadir pre-HAART categories, % | |||||
| >500 | 5.1 | 4.9 | 5.2 | 5.9 | 0.959 |
| 351 ≤ 500 | 12.4 | 12.8 | 12.4 | 9.8 | |
| 201 ≤ 350 | 29.6 | 30.9 | 28.1 | 25.5 | |
| ≤200 | 52.9 | 51.4 | 54.2 | 58.8 | |
| Baseline HIV-RNA copies/mL Median [IQR] | 61187 [13727–168932] | 60162 [12122–185684] | 62472 [16357–151974] | 63997 [14251–124307] | 0.974 |
| Baseline HIV-RNA categories, % | |||||
| <10,000 | 22 | 22.3 | 21.6 | 21.6 | 0.858 |
| 10,000–99,999 | 42.2 | 41 | 42.5 | 49 | |
| >99,999 | 35.8 | 36.7 | 35.9 | 29.4 | |
| Baseline AST median [IQR] | 33.0 [24.0–54.0] | 33.0 [23.0–55.0] | 33.0 [23.0–48.0] | 36.0 [27.0–70.0] | 0.373 |
| Baseline ALT median [IQR] | 24.0 [17.0–41.0] | 25.0 [17.0–42.2] | 24.0 [16.0–40.0] | 25.0 [17.3–43.0] | 0.791 |
| Baseline PLT median [IQR] | 203.0 [164.0–256.0] | 197.0 [158.0–248.5] | 213.0 [175.0–267.0] | 207.0 [167.0–266.0] | 0.308 |
| Median FIB 4 at baseline [IQR] | 1.4 [0.9–2.1] | 1.5 [1.0–2.2] | 1.2 [0.8–1.8] | 1.5 [0.9–2.3] | <0.001 |
| FIB-4 category at baseline | |||||
| <1.45 | 52.9 | 49.4 | 63 | 45.1 | 0.044 |
| 1.45–3.25 | 34.7 | 36.9 | 28.6 | 39.2 | |
| ≥ 3.25 | 12.4 | 13.7 | 8.4 | 15.7 | |
| Number of drinking days/week, % | |||||
| <1 | 80.9 | 100 | 62.3 | 24.5 | <0.001 |
| 1–3 | 13.4 | 0 | 33.1 | 28.6 | |
| >3 | 5.7 | 0 | 4.6 | 46.9 | |
| HAART regimen,% | |||||
| PI+NRTI | 48.2 | 47.1 | 51 | 47.1 | 0.818 |
| NNRTI+NRTI | 50.9 | 51.7 | 49 | 51 | |
| Any INSTIa, % | 1.7 | 2.4 | 0.6 | 0 | 0.369 |
| Diabetes,% | 8.8 | 11 | 3.9 | 9.8 | 0.025 |
| Hepatitis C,% | 40.9 | 44.5 | 27.9 | 56.9 | <0.001 |
a
INSTI, Integrase Inhibitor.
*
p Values are for ANOVAs (for comparison of means), Kruskar Wallis tests (for comparison of medians) and χ2 tests (for comparison of proportions).